Aims+Scope/Editorial Board/ Publication information
(Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - March 14, 2024 Category: Radiology Source Type: research
Contents
(Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - March 14, 2024 Category: Radiology Source Type: research
Professional development through mentoring: Final evaluation of the pilot mentoring programme of the European society of radiotherapy and oncology
A large body of literature exists on the importance of mentoring in healthcare. It is increasingly recognized as a bidirectional process where both mentors and mentees benefit. Benefits for the mentees include increased self-efficacy, job satisfaction and productivity at work, while mentors can benefit through personal fulfilment, and the development of leadership and coaching skills [1]. These advantages are also pertinent for radiation oncology (RO). While mentorship appears to be exceptionally valuable also in RO, it remains understudied [2 –4]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - March 14, 2024 Category: Radiology Authors: Steven F. Petit, Daniel Portik, Azadeh Abravan, Jenny Bertholet, Dylan Callens, Ludwig Dubois, Pierfrancesco Franco, Morten Horsholt Kristensen, Pierre Montay-Gruel, Daan Nevens, Sophie Perryck, Kathrine R øe Redalen, Bartłomiej Tomasik, Amanda Webster, Tags: Short Communication Source Type: research
Clinical practicality and patient performance for surface-guided automated VMAT gating for DIBH breast cancer radiotherapy
Radiotherapy (RT) is applied after breast-conserving surgery to enhance local control and overall survival in breast cancer patients [1]. As a consequence and particularly among patients with left-sided breast cancer, radiation dose is incidental partially delivered to the heart and lungs, which is known to increase the risk of cardiovascular and lung disease [2,3]. Advanced radiation techniques like volumetric modulated arc therapy (VMAT) have been developed to deliver more precise and conformal doses to better spare the heart and lungs [4 –6]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - March 14, 2024 Category: Radiology Authors: Sophie Huijskens, Patrick Granton, Kimm Fremeijer, Cynthia van Wanrooij, Kirsten Offereins-van Harten, Suzanne Schouwenaars-van den Beemd, Mischa Hoogeman, Margriet G.A. Sattler, Joan Penninkhof Tags: Original Article Source Type: research
ESTRO-SIOPE guideline: Clinical management of radiotherapy in atypical teratoid/rhabdoid tumors (AT/RTs)
Atypical teratoid/rhabdoid tumors (AT/RT) are tumors of the central nervous system (CNS) most commonly diagnosed in very young children [1 –5], with most (70–80 %) tumors found in children under three years of age [6,7]. The German Childhood Cancer Registry reported that the median age at diagnoses was 18 months [8]. These rare embryonal tumors are locally aggressive and one of the most malignant CNS tumors. Also, they spread t hroughout the CNS by cerebrospinal fluid (CSF). Up to one-third of the patients have disseminated disease in the brain or spinal canal or both at diagnosis [9,10]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - March 13, 2024 Category: Radiology Authors: Beate Timmermann, Claire Alapetite, Karin Dieckmann, Rolf-Dieter Kortmann, Yasmin Lassen-Ramshad, John H. Maduro, Monica Ramos Albiac, Umberto Ricardi, Damien C. Weber Tags: Original Article Source Type: research
Proposals for the delineation of neck clinical target volume for definitive Radiation therapy in patients with oral/ oropharyngeal squamous cell cancer based on lymph node distribution
Oral squamous cell carcinoma (OSCC) and oropharyngeal squamous cell carcinoma (OPSCC) are the most common types of head and neck cancer [1], constituted 2.5 % of global malignancies in 2018 [2]. Approximately 60 % of OSCC/OPSCC cases are diagnosed as locally advanced, with 50 % considered unresectable [3]. In addition, over 50 % of these cases exhibit cervical lymph node metastasis (LNM) upon initial diagnosis, with the risk varying based on th e tumor location, size, and pathological characteristics [4,5]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - March 13, 2024 Category: Radiology Authors: Yun-Chang Liu, Xin Zhang, Hao-Nan Yang, Lu Zhang, Dan Li, Meng-Qi Yang, Nuo-Han Wang, Yong-Zhong Wu, Jiang-Dong Sui, Ying Wang Tags: Original Article Source Type: research
A population-based analysis of the impact of 1 vs. 2 doses of mitomycin on patterns of failure of anal cancer patients treated with concurrent chemoradiotherapy
Anal cancer (AC) is an uncommon malignancy accounting for about 2.6% of all gastrointestinal (GI) tract cancers, with squamous cell carcinoma (SCC) being the most common histological type [1]. Although relatively rare, it is well documented that the incidence of AC is rising, notably in higher income countries [2,3]. Definitive chemoradiotherapy (CRT) with 5-fluorouracil and mitomycin-C (5FU/MMC) is the treatment of choice for non-metastatic anal canal SCC (ASCC). CRT is an alternative strategy to abdominoperineal resection that preserves the anatomical sphincter in up to 80 % of cases, and results in significantly improve...
Source: Radiotherapy and Oncology - March 11, 2024 Category: Radiology Authors: Kurian Joseph, Zainab Al Habsi, Aswin Abraham, Arun Elangovan, Sunita Ghosh, Truo-Mingh Pham, Devika Shreekumar, Zeyana Ramji, Kim Paulson, Keith Tankel, Nawaid Usmani, Diane Severin, Dan Schiller, Clarence Wong, Karen Mulder, Hatim Karachiwala, Corinne D Tags: Original Article Source Type: research
Predicting overall survival and prophylactic cranial irradiation benefit in small-cell lung cancer with CT-based deep learning: A retrospective multicenter study
Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States alone in 2022, it accounted for approximately 130,180 fatalities, constituting 21% of all cancer-related mortality [1]. Small-cell lung cancer (SCLC), a subtype of lung cancer, is a highly aggressive neuroendocrine tumor with poor differentiation. It tends to metastasize early and has an unfavorable prognosis, accounting for roughly 15% of all lung cancer cases [2,3]. Currently, SCLC is categorized into limited and extensive stages according to the widely accepted staging criteria of the Veteran Affairs Lung Group, with extensive...
Source: Radiotherapy and Oncology - March 11, 2024 Category: Radiology Authors: Xiaomin Zheng, Kaicai Liu, Na Shen, Yankun Gao, Chao Zhu, Cuiping Li, Chang Rong, Shuai Li, Baoxin Qian, Jianying Li, Xingwang Wu Tags: Original Article Source Type: research
A systematic review of circulating predictive and prognostic biomarkers to aid the personalised use of radiotherapy in the radical treatment of patients with oesophageal cancer
Oesophageal cancer is the sixth leading cause of cancer-related death worldwide, accounting for an annual global burden of around 544,000 deaths [1]. There are two major subtypes, oesophageal adenocarcinoma (OAC) and oesophageal squamous cell carcinoma (OSCC). Treatment approaches increasingly diverge between these subtypes, though radiotherapy (RT) is an important component of available therapeutic strategies for both. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - March 11, 2024 Category: Radiology Authors: Dylan McClurg, Chandan Sanghera, Somnath Mukherjee, Rebecca C. Fitzgerald, Christopher M. Jones Tags: Original Article Source Type: research
Dosimetric impact of bone marrow sparing for robustly optimized IMPT for locally advanced cervical cancer
Standard treatment of locally advanced cervical cancer (LACC) combines external beam radiotherapy, cisplatin-based concurrent chemotherapy, and image-guided brachytherapy [1]. Although this treatment combination provides a good clinical outcome in terms of local and pelvic tumor control [2,3], it is associated with a high incidence of morbidities, including gastrointestinal (GI) and genitourinary (GU) toxicities as well as hematologic toxicity (HT) [4,5]. HT, and more specifically radiation-induced lymphopenia, has been associated with a poorer prognosis on overall survival [6,7]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - March 10, 2024 Category: Radiology Authors: S.C. Kuipers, J. Godart, A. Corbeau, S. Breedveld, J.W.M. Mens, S.M. de Boer, R.A. Nout, M.S. Hoogeman Tags: Original Article Source Type: research
Longitudinal changes in the carotid arteries of head and neck cancer patients following radiation therapy: Results from a prospective serial imaging biomarker characterization study
Radiation therapy (RT) is an integral part of the treatment of head and neck cancer [1]. Most patients require treatment to the cervical lymph nodes adjacent to the carotid arteries, which most often cannot be excluded from the RT volume. This increases the risk for accelerated atherosclerosis, carotid artery stenosis and subsequent transient ischemic attack (TIA) and cerebrovascular accident (CVA) [2,3]. The long latent interval of several years from RT to the development of carotid artery stenosis makes it difficult to identify patients who will develop adverse outcomes [4,5]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - March 9, 2024 Category: Radiology Authors: Efstratios Koutroumpakis, Abdallah Sherif Radwan Mohamed, Peter Chaftari, David I. Rosenthal, Dorothy Gujral, Christopher Nutting, Serageldin Kamel, Mohamed A. Naser, Peter Kim, Roland Bassett, Clifton D. Fuller, Elie Mouhayar, MD Anderson Head Neck Radia Tags: Original Article Source Type: research
Optimal hypofractionated radiation therapy schemes for early-stage hepatocellular carcinoma
Hepatobiliary cancer is the second leading cause of cancer death worldwide [1]. The majority ( ∼90 %) of hepatobiliary cancer is hepatocellular carcinoma (HCC) which may result in liver cirrhosis. The major risk factors are chronic infection of hepatitis B and C viruses in Asia, while chronic heavy alcohol use, obesity, and diabetes in the USA and Europe. Despite of improved HCC screening , prevention, and treatment of the risk factors, the incurrence and mortality rates continue to rise. The treatment options for patients with early-stage hepatobiliary cancer are surgery, transplantation, and/or ablation. (Source: Rad...
Source: Radiotherapy and Oncology - March 9, 2024 Category: Radiology Authors: Feng Liu, Doris R. Brown, Michael T. Munley Tags: Original Article Source Type: research
Dose-response of localized renal cell carcinoma after stereotactic body radiation therapy: A meta-analysis
Renal cell carcinoma (RCC) is the most common malignancy of the kidney, with an estimated 79,000 new cases and 13,920 deaths in the United States in 2022. [1] Over the last two decades, the incidence of RCC has continued to increase by 2 % annually, with a calculated global age-standardized mortality rate of 1.8/100,000. [2] Surgical resection with radical or partial nephrectomy remains the standard of care for the initial management of primary RCC. [3] However, surgery may not be feasible for all patients, particularly those who are elderly, have impaired kidney function, or possess significant comorbidities, which com...
Source: Radiotherapy and Oncology - March 8, 2024 Category: Radiology Authors: Ryan S. Huang, Ronald Chow, Pradnya Chopade, Andrew Mihalache, Asad Hasan, Gabriel Boldt, Rachel Glicksman, Charles B. Simone, Michael Lock, Srinivas Raman Tags: Meta-analysis Source Type: research
Very accelerated partial breast irradiation in 1 or 2 days: Late toxicity and early oncological outcome of the GEC-ESTRO VAPBI cohort
In 2020, with 2.26 million new cases, breast cancer was the most commonly diagnosed cancer and the leading cause of cancer death in women (684,996) [1]. Forecasts for 2040 predict 3.19 million (30 % increase) new cancer cases and 1.04 million (34 % increase) cancer deaths [2]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - March 7, 2024 Category: Radiology Authors: Jean-Michel Hannoun-Levi, Marta Gimeno Morales, Jocelyn Gal, Javier Anchuelo, Jose-Luis Guinot, Miren Gazta ñaga, Norbert Meszaros, Csaba Polgar, Vratislav Strnad, Renaud Schiappa, Cristina Gutierrez Tags: Original Article Source Type: research
Very accelerated partial breast irradiation in 1 or 2 days: Late toxicity and early oncological outcome of the GEC-ESTRO VAPBI cohort
In 2020, with 2.26 million new cases, breast cancer was the most commonly diagnosed cancer and the leading cause of cancer death in women (684,996) [1]. Forecasts for 2040 predict 3.19 million (30% increase) new cancer cases and 1.04 million (34% increase) cancer deaths [2]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - March 7, 2024 Category: Radiology Authors: Jean-Michel Hannoun-Levi, Marta Gimeno Morales, Jocelyn Gal, Javier Anchuelo, Jose-Luis Guinot, Miren Gastanaga, Norbert Meszaros, Csaba Polgar, Vratislav Strnad, Renaud Schiappa, Cristina Gutierrez Tags: Original Article Source Type: research
